The University of California, San Diego Pediatric AIDS Clinical Trials Unit (UCSD Pediatric ACTU) proposes to continue its participation in the AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. We have hired an outstanding group of health- professionals, established clinical programs and developed outreach activities that are necessary for the implementation and successful completion of clinical studies for HIV-infected children. Members of the UCSD Pediatric ACTU have made important contributions to the planning, development, implementation and analysis of clinical studies encompassing a broad range of ACTG pediatric protocols. Additionally, members of our Unit have participated in 19 different ACTG committees and working groups, and have been members of 13 different protocol teams. We propose to continue our high-level of participation in studies: to evaluate antiretrovirals, to prevent and treat opportunistic infections and serious bacterial infections, and to prevent maternal-infant transmission. Additionally, we will initiate studies to evaluate candidate HIV vaccines when they become available. All children and pregnant women infected with HIV followed by our Mother/Child clinic are potentially eligible for participation in ACTG protocols. Thus, participants recruited to clinical studies are representative of populations most affected by the AIDS epidemic in San Diego County including minority women and children, substance users, and persons with hemophilia. The continued participation of the UCSD Pediatric ACTU in the ACTG will enable our Unit to continue to make important contributions to the overall effort to develop improved treatments for women and children infected with HIV.

Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Saitoh, Akihiko; Capparelli, Edmund; Aweeka, Francesca et al. (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285-9
Saitoh, Akihiko; Foca, Marc; Viani, Rolando M et al. (2008) Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics 121:e513-21
Saitoh, Akihiko; Haas, Richard H; Naviaux, Robert K et al. (2008) Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 52:2825-30
Hitti, Jane; Andersen, Janet; McComsey, Grace et al. (2007) Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol 196:331.e1-7
Saitoh, Akihiko; Sarles, Elizabeth; Capparelli, Edmund et al. (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21:2191-9
Singh, K K; Spector, S A (2007) Fidelity of whole-genome amplification of blood spot DNA for HLA typing and SNP analyses. Clin Genet 72:156-9
Saitoh, Akihiko; Fletcher, Courtney V; Brundage, Richard et al. (2007) Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 45:280-5
Seage 3rd, George R; Buchacz, Kate; Weinberg, Geoffrey A et al. (2006) The Pediatric AIDS Severity Score (PASS): a multidimensional AIDS-severity adjustment for pediatric HIV infection. J Acquir Immune Defic Syndr 43:603-10
Patel, Kunjal; Weinberg, Geoffrey A; Buchacz, Kate et al. (2006) Simple Pediatric AIDS Severity Score (PASS): a pediatric severity score for resource-limited settings. J Acquir Immune Defic Syndr 43:611-7
Saitoh, Akihiko; Singh, Kumud K; Sandall, Sharsti et al. (2006) Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy. J Allergy Clin Immunol 117:909-15

Showing the most recent 10 out of 55 publications